Comparison of Bleeding Profiles of Sugammadex and Neostigmine in
Orthotopic Liver Transplantation
H Liang, DO, R Chadha, MD, L White, J.R Renew, MD FASA FASE
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT :
Sugammadex is known to prolong prothrombin time (PT) and activated
thromboplastin time (aPTT); however, there are still controversies about
the relation between sugammadex and bleeding. Liver transplant
recipients often present with abnormal coagulation profiles and other
comorbidities before liver transplantation and have a higher risk of
postoperative bleeding. We compare bleeding risk associated with
sugammadex versus neostigmine during liver transplantation.
WHAT THIS STUDY ADDS :
Our retrospective study results demonstrate that sugammadex is not
associated with increased postoperative bleeding events, had less PONV,
did not affect the organ rejection rate, and did not affect hospital
length of stay. We provide incremental evidence sugammadex can be
considered as an alternative to antagonize neuromuscular blockade
following orthotopic liver transplantation.